Merus N.V.
MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumorā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$66.82
Price+1.72%
$1.13
1Y
Price
Market Cap
$4.977b
Mid
Price/Earnings 3y Avg5y Avg
-20x
Premium
Premium
Dividends
Ex-Dividend: -0.00%
Yield$0.00
Dividend0.00%
Forward Dividend Growth 3y CAGR5y CAGR
0.0%
Premium
Premium
Payout Payout 3yPayout 5y
0.0%
Premium
Premium
Yield
BenchmarkDividends
No items found.
Financials Overview
Key metrics over the past few years-650.9%
EBITDA Margin-682.5%
Net Profit Margin-
Free Cash Flow MarginRevenue
$36.133m
-19.9%
1y CAGR-9.8%
3y CAGR+8.6%
5y CAGREarnings
-$215.326m
-8.2%
1y CAGR-40.9%
3y CAGR-25.2%
5y CAGREPS
-$3.34
+4.3%
1y CAGR-22.4%
3y CAGR-6.6%
5y CAGRBook Value
$647.927m
$782.693m
Assets$134.766m
Liabilities$9.912m
DebtDebt to Assets
1.3%
-
Debt to EBITDAFree Cash Flow
-$187.504m
+26.9%
1y CAGR-42.1%
3y CAGR-25.2%
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases
Statements and updates from the company